このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Procter & Gamble Health マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Milind Thatte

最高経営責任者

₹25.2m

報酬総額

CEO給与比率	100.0%
CEO在任期間	6.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	5.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Procter & Gamble Health の収益と比較して、Milind Thatte の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	₹25m	₹25m	₹2b
Mar 31 2023	n/a	n/a	₹2b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	₹39m	₹39m	₹2b
Mar 31 2022	n/a	n/a	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	₹32m	₹32m	₹2b
Mar 31 2021	n/a	n/a	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	₹17m	₹26m	₹2b
Mar 31 2020	n/a	n/a	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹1b
Mar 31 2019	n/a	n/a	₹1b
Dec 31 2018	₹20m	₹13m	₹1b

報酬と市場: Milindの総報酬 ($USD 301.86K ) は、 Indian市場 ($USD 380.55K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Milindの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Milind Thatte (55 yo)

6.3yrs

在職期間

₹25,184,000

報酬

Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...

取締役

名称	ポジション	在職期間	報酬	所有権
Milind Thatte	MD & Executive Director	6.3yrs	₹25.18m	データなし
Lokesh Chandak	CFO, Finance Head & Executive Director	1.3yrs	₹27.76m	データなし
Suresh Talwar	Non-Executive Independent Chairman of the Board	40.6yrs	₹2.38m	0.036% ₹ 30.8m
Subramanian Madhavan	Non-Executive Independent Director	2.8yrs	₹2.13m	データなし
Rani Jadhav	Non-Executive Independent Director	9.5yrs	₹2.20m	データなし
Aalok Agrawal	Non-Executive Director	5.2yrs	データなし	データなし
Seema Sambasivan	Non-Executive Director	1.3yrs	データなし	データなし

5.2yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: 500126の取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Procter & Gamble Health マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Procter & Gamble Health Limited to Report Q4, 2024 Results on Aug 21, 2024

Third quarter 2024 earnings released: EPS: ₹28.00 (vs ₹35.70 in 3Q 2023)

Procter & Gamble Health Limited to Report Q3, 2024 Results on May 02, 2024

Second quarter 2024 earnings released: EPS: ₹43.40 (vs ₹46.30 in 2Q 2023)

Procter & Gamble Health Limited Declares Special Dividend for the Financial Year 2023-24, Payable on or Before March 3, 2024

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited to Report Q1, 2024 Results on Nov 03, 2023

Procter & Gamble Health Limited Recommends Final Dividend,Payable Between November 28, 2023 to December 18, 2023

Full year 2023 earnings released: EPS: ₹138 (vs ₹116 in FY 2022)

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Procter & Gamble Health Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Third quarter 2023 earnings released: EPS: ₹35.70 (vs ₹30.80 in 3Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Procter & Gamble Health Limited Recommends an Interim Dividend for the Financial Year 2022-23, Payable on or Before March 05, 2023

Second quarter 2023 earnings released: EPS: ₹46.30 (vs ₹27.00 in 2Q 2022)

Less than half of directors are independent

First quarter 2023 earnings released: EPS: ₹38.30 (vs ₹33.40 in 1Q 2022)

Upcoming dividend of ₹11.50 per share

Procter & Gamble Health Limited to Report Q3, 2022 Results on Nov 09, 2022

Procter & Gamble Health Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: EPS: ₹116 (vs ₹107 in FY 2021)

Procter & Gamble Health Limited Recommends Final Dividend for the Financial Year Ended June 30, 2022, Payable Between November 28, 2022 to December 18, 2022

Procter & Gamble Health Limited to Report Fiscal Year 2022 Results on Aug 29, 2022

Procter & Gamble Health Limited Recommends Interim Dividend for the Financial Year 2021-22, payable on or before May 31, 2022

Third quarter 2022 earnings released: EPS: ₹30.80 (vs ₹9.50 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹130 per share

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Non-Executive Director Sujay Wasan has left the company

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Procter & Gamble Health Limited Recommends One-Time Special Dividend for the Financial Year Ended June 30, 2021

Company Secretary & Compliance Officer Preeti Bishnoi has left the company

New 90-day low: ₹6,562

Second quarter 2021 earnings released: EPS ₹40.90 (vs ₹23.02 in 2Q 2020)

New 90-day high: ₹7,315

New 90-day high: ₹7,107

New 90-day high: ₹7,030

First quarter 2021 earnings released: EPS ₹35.70

New 90-day high: ₹5,682

Full year earnings released - EPS ₹99.98

New 90-day high - ₹5,251

Procter & Gamble Health Limited to Report Q2, 2020 Results on Sep 15, 2020

New 90-day high - ₹4,879

New 90-day high - ₹4,402

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34